Mochida Pharmaceutical Co Ltd represents a strong commitment to health and innovation. With a corporate philosophy centered on "Contributing to medical care and human health through the development and provision of pharmaceuticals," Mochida continuously strives to improve patients' quality of life. The company values integrity, responsibility, and sustainability in delivering high-quality, patient-centric healthcare solutions. Mochida Pharmaceutical Co Ltd is dedicated to conducting research and development to meet the diverse and evolving needs of healthcare professionals and patients worldwide, making them a trusted and respected player in the pharmaceutical industry.

Mochida Pharmaceutical Co Ltd is primarily present in Japan. As a leading pharmaceutical company, Mochida operates within its domestic market and focuses on delivering innovative healthcare solutions to patients across Japan. With a strong foundation and extensive expertise in the Japanese healthcare industry, Mochida remains dedicated to enhancing the well-being of its customers and contributing to the advancement of medical science.

Mochida Pharmaceutical Co Ltd has achieved several significant milestones throughout its history. The company, which was established in 1919, has gained recognition not only in Japan but also internationally. One notable milestone is the development and launch of their flagship product, Ibuprofen, in 1961. Mochida Pharmaceutical Co Ltd has also expanded its business globally, establishing subsidiaries and partnerships in various countries. In recent years, the company has focused on research and development, bringing innovative drugs and medical solutions to the market. Mochida Pharmaceutical Co Ltd continues to excel in the pharmaceutical industry, making continuous strides towards improving healthcare worldwide.

Mochida Pharmaceutical Co Ltd is a Japanese pharmaceutical company with a rich history and background. Founded in 1919, Mochida Pharmaceutical has been dedicated to improving public health through the development and production of innovative medicines. With over a century of experience, they have become recognized for their expertise in various therapeutic areas, including central nervous system disorders, cardiovascular diseases, and oncology. Mochida Pharmaceutical's commitment to research and development has led to the introduction of numerous groundbreaking drugs that contribute to the well-being of people worldwide. Continuously expanding its global presence, Mochida Pharmaceutical remains at the forefront of the pharmaceutical industry with its unwavering dedication to innovation, quality, and patient care.

The main competitors of Mochida Pharmaceutical Co Ltd in the market include established pharmaceutical companies like Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, Astellas Pharma Inc., and Otsuka Pharmaceutical Co., Ltd. These competitors operate in the same industry and offer a range of products and services similar to Mochida Pharmaceutical Co Ltd. In a highly competitive market, Mochida Pharmaceutical Co Ltd strives to differentiate itself through its innovative research and development initiatives, strategic partnerships, and focus on delivering high-quality healthcare solutions to meet the evolving needs of patients and healthcare professionals.

Mochida Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

Mochida Pharmaceutical Co Ltd operates under a diversified business model within the pharmaceutical industry. The company primarily focuses on the research, development, manufacture, and sale of a wide range of pharmaceutical products. They specialize in various therapeutic areas including respiratory, cardiovascular, gastrointestinal, and central nervous system disorders. Mochida Pharmaceutical also engages in the production and distribution of medical devices and clinical diagnostic reagents. The company strives to improve public health by providing safe and effective medicines and medical products. With its strong commitment to research and development, Mochida Pharmaceutical continues to innovate and contribute to the well-being of society.

Mochida Pharmaceutical Co KGV ir 26,58.

Mochida Pharmaceutical Co KUV ir 1,17.

AlleAktien kvalitātes vērtējums Mochida Pharmaceutical Co ir 2/10.

Mochida Pharmaceutical Co apgrozījums ir 102,89 miljardi JPY.

Mochida Pharmaceutical Co peļņa ir 4,55 miljardi JPY.

Mochida Pharmaceutical Co Ltd is a globally active company that specializes in the research, development, production, and marketing of pharmaceutical products. Founded in 1927 in Japan, the company has become one of the leading players in the industry. The business model of Mochida Pharmaceutical Co Ltd is focused on continuous growth and meeting the growing needs and requirements of customers. The core business of the company is the development and production of drugs in the cardiology, oncology, neurology, allergology, and dermatology fields. Mochida Pharmaceutical Co Ltd has outstanding expertise in these areas and works closely with universities and hospitals to develop innovative new therapies. Another important area of Mochida Pharmaceutical Co Ltd's business model is the production of generics. Generics are imitations of original medications produced after the expiration of patent protection. Mochida Pharmaceutical Co Ltd is a significant provider of generics and offers a wide range of medications. Additionally, the company also offers a wide range of diagnostic products, particularly in the field of clinical chemistry. These are tests used to analyze blood and urine samples to monitor patient conditions and diagnose diseases. Mochida Pharmaceutical Co Ltd also has a subsidiary specialized in the production of medical devices. These devices are used for the diagnosis and treatment of diseases, particularly in the cardiology and neurology fields. The company is also involved in the research and development of novel medications and works closely with universities and research institutions. The goal is to develop innovative therapies that enable patients to lead better and healthier lives. The business model of Mochida Pharmaceutical Co Ltd is based on a strategic focus on research and development to create innovative new products and therapies. The company aims to diversify its portfolio and expand its market position. It relies on close collaboration with partners and customers to understand and respond to their needs and requirements. Overall, Mochida Pharmaceutical Co Ltd is a strong company that builds on a wide range of products and services. The company strives to strengthen its position in the market and expand its portfolio to remain successful in the future.

Mochida Pharmaceutical Co izmaksā dividendes 90,00 JPY, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Mochida Pharmaceutical Co vai uzņēmums nedod dividendes.

Mochida Pharmaceutical Co ISIN ir JP3922800002.

Mochida Pharmaceutical Co WKN ir 859288.

Mochida Pharmaceutical Co simbols ir 4534.T.

Pēdējo 12 mēnešu laikā Mochida Pharmaceutical Co maksāja dividendes 80,00 JPY apmērā. Tas atbilst aptuveni 2,37 % dividendes ražībai. Nākamajos 12 mēnešos Mochida Pharmaceutical Co plāno maksāt dividendes 83,96 JPY apmērā.

Mochida Pharmaceutical Co pašreizējā dividendu rentabilitāte ir 2,37 %.

Mochida Pharmaceutical Co maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos oktobris, aprīlis, oktobris, aprīlis.

Mochida Pharmaceutical Co pēdējo 23 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 83,96 JPY. Tas atbilst dividendes ražībai 2,49 %.

Mochida Pharmaceutical Co tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Mochida Pharmaceutical Co apmērā 40 JPY, kas tika izmaksāta 1.12.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 27.09.2024..

Pēdējās dividendes izmaksa notika 1.12.2024..

Gadā 2023, Mochida Pharmaceutical Co izmaksāja 80 JPY dividendes.

Mochida Pharmaceutical Co dividendes tiek izmaksātas JPY.